MorphoSys AG: MorphoSys Presents Interim Results from M-PLAC

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4

Related Keywords

China , Germany , United States , Munich , Bayern , Planegg , American , Brad Rovin , Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Ohio State University , Drug Administration , Morphosys Group , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Us Communications , Meeting Of The American Society Nephrology , American Society , Malte Peters , Chief Research , Development Officer , Membranous Nephropathy , I Mab Biopharma , Janssen Research , Janssen Biotech , Constellation Pharmaceuticals , Morphosy Annual Report , Rev Dis Prim , Dial Transplant , Formos Med Assoc , Englj Med , Morphosys , Presents , Interim , Results , Rom , Place , Study , Elzartamab , During , Society , Nephrology , Nnual , Meeting ,